UGT1A1 polymorphism has a prognostic effect in patients with stage IB or II uterine cervical cancer and one or no metastatic pelvic nodes receiving irinotecan chemotherapy: a retrospective study.
Hideki MatsuokaRyusuke MurakamiKaoru AbikoKen YamaguchiAkihito HorieJunzo HamanishiTsukasa BabaMasaki MandaiPublished in: BMC cancer (2020)
Irinotecan chemotherapy might be beneficial in patients with cervical cancer, UGT1A1 polymorphisms, and ≤ 1 metastatic lymph nodes.